<DOC>
	<DOCNO>NCT01466231</DOCNO>
	<brief_summary>Everolimus refractory testicular germ cell cancer . Everolimus 10 mg /day/ administer patient progression , unacceptable toxicity , complete response inability subject comply study requirement . Feasibility surgical resection assess every 2 cycle treatment patient partial response .</brief_summary>
	<brief_title>Everolimus Refractory Testicular Germ Cell Cancer</brief_title>
	<detailed_description>Treatment Schedule : Everolimus administer dose 10mg/day orally day . One cycle therapy consist 28 day . Estimated duration treatment : Until progression , unacceptable toxicity , complete response inability subject comply study requirement . Feasibility surgical resection assess every 2 cycle treatment patient partial response .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Men age 18 year old 3 . ECOG performance status : 02 , 4 . Histological confirm extracranial primary germ cell cancer , seminoma , nonseminoma 5 . Rising serum marker ( i.e. , alphafetoprotein human chorionic gonadotropin ) sequential measurement biopsyproven unresectable germ cell cancer 6 . Refractory GCTs e.g . patient relapse highdose chemotherapy patient non fit enough highdose chemotherapy 7 . Primary mediastinal GCTs first relapse 8 . Patient 's disease must amenable cure either surgery chemotherapy opinion investigator , 9 . Measurable disease radiological 10 . Adequate hematologic function define WBC &gt; 4000/mm3 , platelet count &gt; 100 000/mm3 hemoglobin level &gt; 9g/dl . 11 . Adequate liver function define total bilirubin level &lt; 1.5 ULN , ALT , AST &lt; 2,5 ULN adequate renal function define serum creatinine â‰¤ 1.5 x ULN . 12 . At least 2 week must elapse since last radiotherapy and/or chemotherapy study entry , 13 . At least 4 week must elapse since last major surgery 14 . Complete recovery prior surgery , and/or reduction adverse event previous systemic therapy radiotherapy grade 1 , 15 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule , 1 . Patients fit inclusion criterion , 2 . Other prior malignancy except successfully treat non melanoma skin cancer 3 . Prior treatment mTOR inhibitor 4 . No concurrent approve investigational anticancer treatment , include surgery , radiotherapy , chemotherapy , biologicresponse modifier , hormone therapy , immunotherapy 5 . Female patient , 6 . Patients infected Human Immunodeficiency Virus ( HIV ) , 7 . Patients severe acute chronic medical condition , laboratory abnormality would impair , judgment investigator , excess risk associate study treatment , , judgment investigator , would make patient inappropriate entry study , 8 . Inability oral intake , drug absorption ( e.g . malabsorption syndrome ) 9 . Hypersensitivity compound drug , 10 . Sexually active men use effective birth control partner woman childbearing potential . 11 . Patients active CNS metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>refractory germ cell cancer</keyword>
	<keyword>everolimus</keyword>
</DOC>